Our Technology

Our Technology

Poxvirus-based technology platform

Bavarian Nordic has built its foundation around poxviral-based vaccine platform technologies, and in particular our proprietary technology, Modified Vaccinia Ankara – Bavarian Nordic (MVA-BN).

This technology have the potential to support a broad product pipeline in both infectious diseases and cancer immunotherapies and can be manufactured at commercial scale at Bavarian Nordic’s own facility.

Read more on MVA-BN